“…G.C. has received honoraria from Janssen, Probi, and Apsen as an invited speaker; is in receipt of research funding from 10.13039/100007082Pharmavite, 10.13039/501100003144Fonterra, Nestle and Reckitt; and is a paid consultant for 10.13039/501100012030Yakult, Zentiva and Heel pharmaceuticals. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A total of 300 male participants who received any of the following vaccines BNT162b2/Comirnaty, mRNA-1273, ChAdOx1-S/Covishield, COVID-19 Vaccine Janssen/Johnson, or BBIBP-CorV or Covaxin were enrolled in our study. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Die Nachbeobachtungszeit wurde entsprechend dem kürzesten empfohlenen Abstand zwischen der ersten und der zweiten Impfdosis auf 21 Tage nach der Erstimpfung festgelegt. 3.588.318 Personen waren mit BNT162b2 (Tozinameran, Comirnaty®) geimpft worden, 244.913 Personen mit mRNA-1273 (Elasomeran, Spikevax®), 4.376.535 mit ChAdOx1 (Vaxzevria®) und 120.731 mit Ad26.COV2-S (Jcovden®, COVID-19 Vaccine Janssen®). Die Berechnung der Häufigkeiten der vier neurologischen Erkrankungen nach der Impfung ergab kein Sicherheitssignal, d.h. diese Erkrankungen traten nach der Impfung nicht häufiger auf als in der Allgemeinbevölkerung. …”
Enlace del recurso
Enlace del recurso

“…Material and methods: A single-centre, prospective cohort study was conducted in 130 patients with immune-mediated rheumatic disease on treatment with immunomodulators, including RTX, who received the full course of vaccination against SARS-CoV-2 with BioNTech/Pfizer, Moderna/Lonza, AstraZeneca, or Janssen between April and October 2021. Demographic factors such as age, sex, type of immune-mediated disease, immunomodulatory treatment and type of vaccine were analysed, as well as serological markers including anti-SARS-CoV-2 IgG antibody levels measured one and six months after vaccination, CD19+ lymphocyte levels and the presence or absence of hypogammaglobulinemia. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RESULTS: There were 162 respondents with an average age of 26.52% with 66.7% of participants being female. 96% of doctors were vaccinated, 87.3% of them with 2 doses. 74% were vaccinated by Sinopharm, 23.5% by Astra Zeneca, 9.4% by Pfizer and 0.7% by Janssen. 68% had post-vaccination side effects. For unvaccinated doctors, 43% say they are not convinced of its usefulness, 28.5% find that there is not enough experience on its effectiveness and 14.3% report that they have a disease that contraindicates the vaccine. …”
Enlace del recurso
Enlace del recurso

“…Pfizer-Biontech was the vaccine manufacturer in 62% of reports, Moderna - in 27%, Janssen - in 10%, and other manufacturers - in 1% of reports. …”
Enlace del recurso
Enlace del recurso

“…DISCLOSURES: Lori Lerner, MD, Janssen Pharmaceutical: Grant/Research Support Kalpana Gupta, MD, MPH, GSK: Advisor/Consultant|IDSA UTI Guidelines: Advisor/Consultant|qiagen: Advisor/Consultant|UpToDate: Advisor/Consultant…”
Enlace del recurso
Enlace del recurso

“…Rana, MD, Merck: Grant/Research Support JEWEL SAWYER, PA-C, MSHS, AAHIVS, Janssen: Speakers Bureau|Prime Education: Speakers Bureau…”
Enlace del recurso
Enlace del recurso

“…DISCLOSURES: Jessica A. Altamirano, MD, Janssen Pharmaceuticals: Speaker's Bureau…”
Enlace del recurso
Enlace del recurso

“…DISCLOSURES: Melody Smith, MD, MS, BMS: Advisor/Consultant Krista Rowe-Nichols, RN, MSN, AOCNS, Bristol Myers Squibb: Advisor/Consultant|Kite Pharmaceuticals: Advisor/Consultant|Kite Pharmaceuticals: Speaker Bureau Christopher Kelsey, MD, Colgate-Palmolive: Expert Testimony|Johnson and Johnson: Expert Testimony Taewoong Choi, MD, Janssen biotech: Honoraria Matthew McKinney, MD, ADC Therapeutics: Advisor/Consultant|ADC Therapeutics: Honoraria|Beigene: Grant/Research Support|Beigene: Honoraria|Epizyme: Advisor/Consultant|Genentech: Advisor/Consultant|Genentech: Grant/Research Support|Genentech: Honoraria|Gilead/Kite: Advisor/Consultant|Gilead/Kite: Honoraria|Incyte: Grant/Research Support|Novartis: Advisor/Consultant|Seagen, Inc.: Advisor/Consultant|Takeda: Advisor/Consultant|TG therapeutics: Advisor/Consultant…”
Enlace del recurso
Enlace del recurso

“…[Figure: see text] DISCLOSURES: Antonella Castagna, MD, Bristol-Myers Squibb: consultancy payments and speaking fees|Gilead: consultancy payments and speaking fees|Janssen-Cilag: consultancy payments and speaking fees|Merck Sharp & Dohme: consultancy payments and speaking fees|ViiV Healthcare: consultancy payments and speaking fees…”
Enlace del recurso
Enlace del recurso

“…Lauffenburger, PhD, Sanofi: Board Member|Sanofi: Honoraria|Sanofi: Honoraria Zachary Wallace, MD, MSc, Bristol-Myers Squibb: Grant/Research Support|Horizon: Advisor/Consultant|MedPace: Advisor/Consultant|Principia/Sanofi: Grant/Research Support|Sanofi: Advisor/Consultant|Shionogi: Advisor/Consultant|Viela Bio: Advisor/Consultant|Zenas BioPharma: Advisor/Consultant Jeffrey Sparks, MD, AbbVie: Advisor/Consultant|Amgen: Advisor/Consultant|Boehringer Ingelheim: Advisor/Consultant|Bristol Myers Squibb: Advisor/Consultant|Bristol Myers Squibb: Grant/Research Support|Gilead: Advisor/Consultant|Inova Diagnostics: Advisor/Consultant|Janssen: Advisor/Consultant|Optum: Advisor/Consultant|Pfizer: Advisor/Consultant Galit Alter, PhD, Leyden Labs: Ownership Interest|Moderna Therapeutics: Employee|Seromyx Systems: Ownership Interest…”
Enlace del recurso
Enlace del recurso

“…Since October 1, 2022, 3,087 patients had SARS-CoV-2 variants characterized including 986 after bivalent vaccination, 1,191 who were fully vaccinated (including Janssen), but not boosted and didn’t receive a bivalent vaccine dose, and 910 who were never vaccinated (Figure 2) according to VA records. …”
Enlace del recurso
Enlace del recurso

“…DISCLOSURES: Michael Virata, MD, Gilead Sciences: Advisor/Consultant|Janssen: Advisor/Consultant|ViiV Healthcare: Advisor/Consultant…”
Enlace del recurso
Enlace del recurso

“…McComsey, MD, Gilead Sciences: Advisor/Consultant|Gilead Sciences: Grant/Research Support|Janssen: Advisor/Consultant|Merck: Advisor/Consultant|Merck: Grant/Research Support|ViiV Healthcare: Advisor/Consultant|ViiV Healthcare: Grant/Research Support…”
Enlace del recurso
Enlace del recurso

“…Okulicz, MD, Gilead Sciences: Advisor/Consultant JEWEL SAWYER, PA-C, MSHS, AAHIVS, Janssen: Speakers Bureau|Prime Education: Speakers Bureau…”
Enlace del recurso
Enlace del recurso

“…DISCLOSURES: Dora Martinez, MD, FAAFP, AAHIVS, Gilead Sciences: Advisor/Consultant|Gilead Sciences: Honoraria|Janssen: Honoraria|ViiV Healthcare: Advisor/Consultant|ViiV Healthcare: Honoraria|ViiV Healthcare: As of May 16th will be employed by ViiV, however was not a ViiV employee at time of project Arianna Inurritegui-Lint, -, Gilead Sciences, Inc.: Advisor/Consultant|Human Rights Campaign Foundation: Advisor/Consultant|National Minority AIDS Council: Advisor/Consultant|ViiV Healthcare: Advisor/Consultant…”
Enlace del recurso
Enlace del recurso

“…Doernberg, MD, MAS, Basilea: Clinical events committee/adjudication committee participation|F2G: Grant/Research Support|Genentech: Advisor/Consultant|Gilead: Grant/Research Support|Janssen/J+J: Advisor/Consultant|Pfizer: Grant/Research Support|Regeneron: Grant/Research Support|Shinogi: Clinical events committee/adjudication committee participation…”
Enlace del recurso
Enlace del recurso

“…METHODS: CTC-positive (five or more CTCs/7.5 mL blood; CellSearch®, Janssen Diagnostics) MBC patients starting a new line of systemic treatment were eligible for the study. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…CONCLUSION: Decitabine treatment was efficacious in Chinese patients with MDS with its safety profile comparable to the global studies of decitabine conducted to date. FUNDING: Xian-Janssen Pharmaceutical Ltd. China (a company of Johnson & Johnson). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso